Patents by Inventor Dae-Jung Kang

Dae-Jung Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11268064
    Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: March 8, 2022
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Seung-Hun Lee, Dae-Jung Kang, Jae-Hoon Kang
  • Patent number: 10894086
    Abstract: The present invention relates to a functional hydrated hyaluronic acid and a method for producing 5th generation coated lactic acid bacteria having excellent intestinal mucoadhesive ability and a selective antagonism using the same and, more specifically, to a functional hydrated hyaluronic acid in which components fermented by lactic acid bacteria are captured in hyaluronic acid, which is a natural polymer substance, and a method for producing coated lactic acid bacteria using the same. The quadruply coated lactic acid bacteria coated using the functional hydrated hyaluronic acid according to the present invention is quadruply coated with a water-soluble polymer, a functional hydrated hyaluronic acid, a coating agent having porous particles, and a protein, thereby producing an excellent intestinal mucoadhesive ability, exhibiting an antibacterial action against deleterious bacteria in the intestines, and promoting growth of beneficial bacteria in the intestines.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: January 19, 2021
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Seung-Hun Lee, Dae Jung Kang, Jae-Hoon Kang
  • Publication number: 20190390159
    Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.
    Type: Application
    Filed: September 9, 2019
    Publication date: December 26, 2019
    Inventors: Seung-Hun Lee, Dae-Jung Kang, Jae-Hoon Kang
  • Patent number: 10443033
    Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: October 15, 2019
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Seung-Hun Lee, Dae-Jung Kang, Jae-Hoon Kang
  • Publication number: 20180250412
    Abstract: The present invention relates to a functional hydrated hyaluronic acid and a method for producing 5th generation coated lactic acid bacteria having excellent intestinal mucoadhesive ability and a selective antagonism using the same and, more specifically, to a functional hydrated hyaluronic acid in which components fermented by lactic acid bacteria are captured in hyaluronic acid, which is a natural polymer substance, and a method for producing coated lactic acid bacteria using the same. The quadruply coated lactic acid bacteria coated using the functional hydrated hyaluronic acid according to the present invention is quadruply coated with a water-soluble polymer, a functional hydrated hyaluronic acid, a coating agent having porous particles, and a protein, thereby producing an excellent intestinal mucoadhesive ability, exhibiting an antibacterial action against deleterious bacteria in the intestines, and promoting growth of beneficial bacteria in the intestines.
    Type: Application
    Filed: September 19, 2016
    Publication date: September 6, 2018
    Applicant: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Seung-Hun LEE, Dae Jung KANG, Jae-Hoon KANG
  • Publication number: 20170051247
    Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.
    Type: Application
    Filed: November 7, 2016
    Publication date: February 23, 2017
    Inventors: Seung-Hun Lee, Dae-Jung Kang, Jae-Hoon Kang
  • Publication number: 20160009828
    Abstract: A method for hyaluronic acid having a low degradation rate in a subject body includes culturing Streptococcus dysgalactiae strain 9103 (KCTC11818BP) in a medium including a carbon source and a nitrogen source.
    Type: Application
    Filed: September 21, 2015
    Publication date: January 14, 2016
    Inventors: Dae-Jung KANG, Tae-Yoon Kim, Jae-Hoon Kang
  • Patent number: 8986973
    Abstract: Provided is a Streptococcus dysgalactiae ID9103 strain having accession number KCTC11818BP, and a method of producing hyaluronic acid by culturing the strain to produce hyaluronic acid having an average molecular weight of 10,000,000 Da or more.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: March 24, 2015
    Assignee: Ildong Pharm Co., Ltd.
    Inventors: Dae-Jung Kang, Jong-Hyuk Im, Tae-Yoon Kim, Jae-Hoon Kang
  • Publication number: 20140206040
    Abstract: Provided is a Streptococcus dysgalactiae ID9103 strain having accession number KCTC11818BP, and a method of producing hyaluronic acid by culturing the strain to produce hyaluronic acid having an average molecular weight of 10,000,000 Da or more.
    Type: Application
    Filed: March 26, 2014
    Publication date: July 24, 2014
    Applicant: ILDONG PHARM CO., LTD.
    Inventors: Dae-Jung KANG, Jong-Hyuk IM, Tae-Yoon KIM, Jae-Hoon Kang
  • Patent number: 8530205
    Abstract: The present invention relates to a buffer composition for promoting production of calcitriol or calcifediol, and a method for producing calcitriol or calcifediol using the same. More particularly, the present invention relates to a buffer composition for promoting production of calcitriol or calcifediol comprising a metallic compound, an organic solvent, cyclodextrin, tris(hydroxymethyl)aminomethane, sodium succinate, sodium chloride, magnesium chloride, and water, and a method for producing calcitriol or calcifediol using the same. In the method for producing calcitiriol or calcifediol, the production yield of calcitriol or calcifediol is high, and the bioconversion is carried out in an enzyme reaction system instead of in a microorganism culture system. Thus, it is not required to maintain a sterile state. Also, the separation/purification following the completion of a biocatalytic reaction can be carried out in a cleaner state than the microorganism culture method.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: September 10, 2013
    Assignee: IL Dong Pharm Co., Ltd.
    Inventors: Dae-Jung Kang, Jong-Hyuk Im, Hyun-Jung Jung, Jae-Hoon Kang
  • Publication number: 20120232261
    Abstract: The present invention relates to a method for preparing low molecular weight hyaluronic acid from high molecular weight hyaluronic acid which is produced by Streptococcus sp. ID9102 (KCTC11395BP). The method of the invention for lowering a molecular weight of high molecular hyaluronic acid has a convenient process without the inconvenience of reprocessing for the removal of input materials, or requiring pH treatment, various reaction catalysts, and complicated additional treatment conditions as in a conventional method. The inventive method for lowering the molecular weight has an advantage in that according to a change of a reaction condition using activated carbon, the molecular weight of low molecular weight hyaluronic acid can be variously adjusted. The low molecular weight hyaluronic acid produced by the method of the invention can be produced in accordance with the standards of cosmetics or foods as well as medical supplies.
    Type: Application
    Filed: March 13, 2012
    Publication date: September 13, 2012
    Applicant: ILDONG PHARM CO., LTD.
    Inventors: Dae-Jung Kang, Jong-Hyuk Im, Jae-Hoon Kang
  • Publication number: 20120064584
    Abstract: The present invention relates to a buffer composition for promoting production of calcitriol or calcifediol, and a method for producing calcitriol or calcifediol using the same. More particularly, the present invention relates to a buffer composition for promoting production of calcitriol or calcifediol comprising a metallic compound, an organic solvent, cyclodextrin, tris(hydroxymethyl)aminomethane, sodium succinate, sodium chloride, magnesium chloride, and water, and a method for producing calcitriol or calcifediol using the same. In the method for producing calcitiriol or calcifediol, the production yield of calcitriol or calcifediol is high, and the bioconversion is carried out in an enzyme reaction system instead of in a microorganism culture system. Thus, it is not required to maintain a sterile state. Also, the separation/purification following the completion of a biocatalytic reaction can be carried out in a cleaner state than the microorganism culture method.
    Type: Application
    Filed: June 16, 2011
    Publication date: March 15, 2012
    Applicant: ILDONG PHARM CO., LTD.
    Inventors: Dae-Jung Kang, Jong-Hyuk Im, Hyun-Jung Jung, Jae-Hoon Kang